Ignite Creation Date:
2025-12-24 @ 3:50 PM
Ignite Modification Date:
2025-12-27 @ 3:21 PM
Study NCT ID:
NCT00261092
Status:
COMPLETED
Last Update Posted:
2008-04-15
First Post:
2005-12-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
GEMOX: Oxaliplatin in Pancreatic Cancer
Sponsor:
Sanofi
Organization:
Study Overview
Official Title:
Phase II Multicenter, Open Label Study of Oxaliplatin Combined With Gemcitabine(GEMOX) in Advanced and Metastatic Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary objective:
* To evaluate overall response rate (based on RECIST criterion)
Secondary objective:
* To evaluate time to progression, clinical benefit, quality of life and safety
* To evaluate overall response rate (based on RECIST criterion)
Secondary objective:
* To evaluate time to progression, clinical benefit, quality of life and safety
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: